United States Montelukast API - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states montelukast aPI market size is projected to expand from USD 1.62 billion in 2025 and USD 1.78 billion in 2026 to USD 2.98 billion by 2031, registering a CAGR of 10.85% between 2026 to 2031. This report is Segmented by Product Type (Amorphous, Crystalline), Dosage Form Compatibility (Film-Coated Tablets, Chewable Tablets, Oral Granules, Oral Solutions, Suspensions, Syrups), and Application (Asthma, Allergic Rhinitis, Exercise-Induced Bronchoconstriction, Urticaria and Other Off-Label Use). The Market Forecasts are Provided in Terms of Value (USD).

United States Montelukast API Market Trends and Insights

U.S. Asthma Controller Demand Base

Asthma remains the central demand anchor for the United States montelukast API market because the treated population is large and persistent across both adult and child cohorts. The CDC reported in 2024 that 8.6% of U.S. adults and 6.5% of children had current asthma, which means controller therapy demand remains broad even before allergy-related use is added on top. This patient pool matters because montelukast stays relevant where physicians want an oral controller option or where inhaler use is inconsistent, especially in younger patients. Once a child is stabilized on an oral regimen, caregivers and prescribers often prefer continuity over disruption, which supports repeat ordering behavior in the United States montelukast API market. That continuity is reinforced by regulatory and chemistry review burdens tied to supplier changes, so established formulator and API relationships tend to last longer than spot-price movements alone would suggest.

Generic-First Payer Economics

Generic-first reimbursement structures continue to support the United States montelukast API market because montelukast remains positioned as a low-cost controller option before escalation to higher-cost therapies. In practical terms, step-therapy design can preserve procurement volumes because it inserts montelukast into many treatment pathways before biologics or other premium therapies are authorized. This keeps demand steady even when clinical guidance becomes more selective, since payer logic and physician workflow do not change at the same speed. Aurobindo Pharma’s March 2025 investor presentation showed 297 U.S. DMFs on file as of December 2024 and API revenue of USD 512 million in FY24, which reflects the scale at which regulated-market suppliers are built around sustained generic demand. The result is a market where price pressure is real, but volume persistence remains strong enough to keep the United States montelukast API market on a double-digit growth path.

FDA Boxed Warning On Neuropsychiatric Risk

The existing boxed warning on neuropsychiatric risk continues to limit new prescribing intensity in the United States montelukast API market, especially for allergic rhinitis starts. The GINA 2024 and 2025 strategy reports both retained repeated reminders around neuropsychiatric risk wherever montelukast appeared in treatment pathways, which shows that caution remains embedded in current clinical practice. The main effect is not a collapse in ongoing use, but a tighter filter on who starts therapy and when it is used in rhinitis care. That means the warning changes the mix of demand more than the existence of demand, since established patients with known benefit are often maintained rather than switched. The United States montelukast API market, therefore, absorbs a continuing restraint through slower new-patient conversion rather than through broad discontinuation of existing therapy.

Other drivers and restraints analyzed in the detailed report include:

• Pediatric Chewable And Granule Demand
• Allergy Season Extension And Perennial Rhinitis Burden
• ICS-First Treatment Pathway Shift

Segment Analysis

Crystalline montelukast sodium held 68.87% of product-type demand in 2025, which made it the dominant form in the United States montelukast API market. That lead reflects the continued weight of film-coated tablet manufacturing, where buyers prefer a stable input with well-understood handling, storage, and validation behavior. Crystalline material fits mature generic production lines because those lines are already aligned around repeatable dissolution behavior and long-established chemistry controls. It also benefits from the fact that many approved formulations were built around this form, which makes continuity easier for both API suppliers and finished-dose manufacturers. For that reason, crystalline grades remain the default purchasing choice wherever adult oral solids drive procurement volumes.

The amorphous form is projected to grow at 11.36% CAGR through 2031, which places it ahead of the broader United States montelukast API industry. That faster pace reflects the needs of oral granules, liquids, and other pediatric-friendly formats that require stronger solubility performance and quicker dispersion behavior. The United States montelukast API industry is therefore seeing a gradual shift from a stability-first buying logic toward a format-fit buying logic in selected high-growth contracts. This does not mean crystalline loses relevance, because adult tablets still represent a deep installed base, but it does mean premium demand is moving toward suppliers that can support more specialized solid-state requirements. As combination products and newer pediatric dosage concepts move forward, early capability in amorphous supply is likely to bring better contract durability than commodity crystalline volumes alone.

Crystalline grades also gain support from the practical reality that formulation changes are slow once a product is established. Buyers generally avoid switching the solid-state form in approved products unless the clinical and commercial payoff is clear, because any change can trigger extra chemistry and validation work. That inertia protects existing crystalline relationships in the United States montelukast API market even while amorphous demand rises faster. At the same time, amorphous suppliers can still gain share where new pediatric or liquid-compatible programs are being designed from the start, since they are not held back by legacy formulation choices.

Complete Report Scope:

• By Product Type
  • Amorphous
  • Crystalline
• By Dosage Form Compatibility
  • Film-coated tablets
  • Chewable tablets
  • Oral granules
  • Oral solutions / suspensions / syrups
• By Application
  • Asthma
  • Allergic rhinitis
  • Exercise-induced bronchoconstriction
  • Urticaria and other off-label use

List of Companies Covered in this Report:

• Aarti Pharmalabs Limited
• Aurobindo Pharma
• CarboMer, Inc.
• Chemox Pharma Private Limited
• Cipla
• Dr. Reddy’s Laboratories Limited
• Hikma Pharmaceuticals
• Intas Pharmaceutical
• Lupin
• Manus Aktteva Biopharma
• Merck
• Morepen Laboratories Limited
• MSN Laboratories Private Limited
• Sandoz Group AG
• Shilpa Pharma Lifesciences Limited
• Simson Pharma Limited
• TAPI
• Unichem Laboratories Limited
• Vamsi Labs Limited
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support